Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launches of premium-priced glycopeptides from Pfizer, Theravance/Astellas, and Targanta, as well as next-generation cephalosporins from Johnson & Johnson/Basilea and Cerexa*/Takeda, will take market share from generic vancomycin, the most widely used antibacterial for resistant gram- positive infections.

The new Pharmacor report Emerging Antibacterial Agents finds that the uptake of Pfizer's dalbavancin, Theravance/Astellas's telavancin, Targanta's oritavancin, Johnson & Johnson/Basilea's ceftobiprole, and Cerexa's ceftaroline will be attributable to their improved side-effect profiles and higher potency against drug-resistant staphylococci, namely methicillin- resistant Staphylococcus aureus. The report also finds that the antibacterial market will experience high turnover as generic erosion of several key antibiotic brands will be partially offset by sales growth of current and novel branded agents. Additionally, the continuous evolution of bacterial pathogens and resulting development of drug resistance creates a constant need for the development of new antibiotics.

"Despite a lack of significant innovation, we forecast that the antibacterial pipeline represents more than $3 billion in potential sales by 2015," said Decision Resources analyst Danielle Drayton, Ph.D. "Physicians interviewed unanimously agree that agents with novel mechanisms of action are greatly needed -- particularly agents that are effective against multidrug- resistant gram-negative pathogens -- to ensure the availability of sufficient options to treat bacterial infections over the next ten years."

About Antibacterial Agents

The emergence of drug resistance among bacteria has significantly eroded the effectiveness of current antibiotics. Among the most important areas of current and future medical need are antibiotics that are effective against resistant gram-negative pathogens in the hospital setting and novel oral anti- methicillin-resistant Staphylococcus aureus agents.

About Decision Resources

Decision Resources ( ) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

* On Dec. 14, Forest Laboratories announced its plan to acquire Cerexa, Inc. by Dec. 31, 2006.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, or

Implantable Cardioverter Defibrillator Market Rebounding in Q4 2006

View Now